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2Département d’ophtalmologie, Université d’Aix-Marseille, Marseille, France
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PURPOSE. Corneal tissue shortage has become a major concern worldwide, which has
motivated the search for alternative solutions to eye bank human eyes for corneal
transplantation. Minimally invasive lamellar transplantation and tissue engineering may offer
new opportunities for the rehabilitation of diseased corneas. The aim of this study was to
evaluate the biocompatibility and functionality of stromal lamellar grafts tissue-engineered
(TE) in vitro and transplanted in vivo in the cornea of a feline model.
METHODS. The corneal stromas were engineered in culture from corneal stromal cells using
the self-assembly approach, without the addition of exogenous material or scaffold. Eight
healthy animals underwent two intrastromal grafts in one eye and the contralateral eye was
used as a control. Animals were followed with slit-lamp ophthalmic examination, corneal
esthesiometry and optical coherent tomography. Confocal microscopy, immunofluorescence,
histology, and transmission electron microscopy (TEM) were performed at 4 months.
RESULTS. Four months after transplantation, the TE-stromal grafts were transparent, functional,
and well tolerated by the eye. All grafts remained avascular, with no signs of immune
rejection, despite a short course of low-dose topical steroids. Corneal sensitivity returned to
preoperative level and reinnervation of the grafts was confirmed by confocal microscopy and
immunofluorescence. Histology and TEM of the TE-grafts showed a lamellar stromal structure
with regular collagen fibril arrangement.
CONCLUSIONS. These results open the way to an entirely new therapeutic modality. Intracorneal
filling using a biocompatible, transparent, and malleable TE-stroma could be the basis for
multiple types of novel therapeutic options in corneal interventional surgery.
Keywords: tissue engineering, corneal transplantation, corneal stroma, corneal substitute,
reinnervation, cell culture
Corneal tissue shortage has become a major concernworldwide, the supply of donor tissue clearly not meeting
the increasing demand.1 Alternative solutions to eye bank human
eyes for corneal transplantation are needed, corneal blindness
representing the fourth most important cause of visual
impairment in the world, after cataract, glaucoma and age-
related macular degeneration.2,3 Irreversible corneal damage has
traditionally been treated with full thickness corneal transplan-
tation using eye bank corneas. These standards, however, may
have to change. The growing experience developed in different
parts of the world with lamellar corneal transplantation and with
tissue engineering may open the way to new solutions. Lamellar
transplantation is based on the selective replacement of the
diseased corneal layers. It may relieve some of the pressure on
eye banks by reducing the severity of the exclusion criteria,
which could be limited to specific corneal layers. Tissue
engineering also offers a new and promising opportunity to
overcome tissue shortage, based on the production of trans-
plantable corneal tissue layers, such as epithelium,4,5 endothe-
lium,6–8 or stroma. We herein focused on the concept of lamellar
transplantation of a tissue-engineered (TE) corneal stroma.
Several alternatives to native tissue have been proposed for
corneal stromal replacement. Synthetic, rigid, and inert
keratoprostheses, with transparent optical components usually
made of PMMA or poly[2-hydroxyethyl methacrylate], have
been implanted for several decades in human subjects.
Although these prostheses can restore sight, their prognosis
is overshadowed by a significant risk for infection, dehiscence,
and extrusion, due to the lack of integration of the nonbiolog-
ical material within the host’s corneal tissue.9,10
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A variety of synthetic and acellular biomaterials aimed at
replacing the corneal stroma have been tested experimentally,
with mitigated success. Polyvinyl alcohol hydrogel11 and
expanded polytetrafluoroethylene implants,12 for instance,
offer interesting optical properties and low immunogenicity,
but are compromised by low cell affinity or biocompatibility.
Biocompatibility is improved with polyethylene glycol–diacry-
late13 or type I collagen, chitosan, and glycosaminoglycans14
implants; however, with variable degrees of transparency and
tendency for biodegradation. In an attempt to improve in vivo
stability, corneal stromal cells have been introduced on the
surface or within various substrates, such as synthetic
polymers15 and gelatin hydrogel.16 These results have high-
lighted the benefits of generating cytocompatible biomaterials
in order to improve biointegration of the stromal implant.
An intermediate option, consisting of a cell-free scaffold
permeable to the host’s corneal cells and nerves has been
proposed by Griffith’s group. This stromal substitute made of
cross-linked recombinant human collagen was implanted in 10
human subjects,17 which represents an advance in the field of
stromal replacement.
The new concept proposed herein combines both alterna-
tives of tissue engineering and lamellar transplantation. The
stromal tissue described herein is different and complementary
to that of an acellular biosynthetic implant or scaffold, as it is
entirely engineered from stromal cells (keratocytes) prior to
transplantation. Keratocytes can be isolated and easily expanded
in vitro. When cultured in the presence of serum, they acquire a
fibroblastic phenotype and are called ‘‘corneal fibroblasts.’’18
The self-assembly approach is based on the natural capacity of
corneal stromal fibroblasts to secrete and assemble their own
extracellular matrix without the addition of exogenous bioma-
terial. The stromal sheets generated are then stacked to form a
thicker stromal substitute.19 This approach is now used to
engineer skin transplants for the treatment of severe burns20 and
lower-extremity chronic skin ulcers.21 It is also under investiga-
tion for the engineering of blood vessels22 and adipose tissue.23
The corneal stromal tissue produced with this technique opens
the door to an entirely new generation of therapeutic options for
the rehabilitation of a wide range of diseased corneas.
The aim of this study was to evaluate the biocompatibility
and functionality of this corneal stromal tissue engineered in
vitro using the self-assembly technique and transplanted in vivo
in the cornea of a feline model.
MATERIALS AND METHODS
All experiments were conducted in accordance with the ARVO
statement for the Use of Animals in Ophthalmic and Vision
Research for the duration of all the experiments. The research
protocol was approved by the Maisonneuve-Rosemont Hospi-
tal Animal Protection committee.
Tissue Engineering of the Corneal Stroma
Isolation and Culture of Human and Feline Corneal
Cells. The human corneas of a 26-day-old human donor
unsuitable for transplantation were obtained from our local eye
bank (Banque d’Yeux du Centre Universitaire d’Ophtalmologie,
Québec, QC, Canada). Keratocytes were isolated after dispase
digestion and removal of the epithelium and endothelium. They
were cultured in fibroblast culture medium consisting of DMEM
supplemented with 10% fetal calf serum (Hyclone, Logan, UT,
USA), 25 lg/mL gentamycin sulphate (Schering, Pointe Claire,
QC, Canada), and 100 IU/mL penicillin G (Sigma, Oakville, ON,
Canada).24–26 Feline keratocytes were isolated (n¼1 pair of eyes)
and cultured using the same protocol as for human cells.
Tissue Engineering of Human and Feline Stromas
Using the Self-Assembly Approach. Corneal fibroblasts
were seeded at a density of 100 cells/mm2 and cultured in
fibroblast growth medium supplemented with 50 lg/mL
ascorbic acid (Sigma) for 28 (feline cells) or 35 (human cells)
days. Fibroblasts secreted their own extracellular matrix and
generated thick sheets, six of which were stacked to produce a
thick corneal stroma.26
In Vitro Assessment of Stromal Compatibility With
Neurite Outgrowth. Compatibility with reinnervation was
assessed in vitro. Sensory neurons (given by François Berthod)
were extracted from the dorsal root ganglion (DRG) of mice
embryos (E12.5, CD-1 mice; Charles River Laboratories, Lasalle,
QC, Canada),27 washed, and trypsinized. We seeded 2000 DRG/
mm2 on the tissue-engineered corneal stromas and cultured in
growth medium containing 10 ng/mL nerve growth factor
(Feldan, Québec, QC, Canada) for 14 and 21 days.28 Tissues
were then processed for immunofluorescent labeling. None of
the tissues seeded with DRG were transplanted in vivo.
Population
Eight healthy domestic felines aged between 10.3 and 19.4
months (15.4 6 3.5 months) and weighing between 2.7 and
4.7 kg (3.7 6 0.9 kg) were used for this study. One eye per
animal was randomly assigned to transplantation of two TE-
stromal grafts and the contralateral eye was used as a control.
Four animals received grafts engineered from feline cells
(allografts) and four animals received grafts engineered from
human cells (xenografts).
Surgical Protocol
Surgery was performed under general anesthesia.29 Two limbal
incisions 4-mm long and 300-lm deep were made poles apart
in the superior nasal and inferior temporal quadrants, using a
micrometric diamond knife (Meyco; Anton Meyer & Co., Ltd.,
Biel, Switzerland) and a 7-mm long intrastromal lamellar
dissection was made toward the center of the cornea using a
crescent knife (Alcon Canada, Inc., Mississauga, Canada). Two
TE-stromal grafts were cut (4-mm Acupunch; Acuderm, Inc.,
Fort Lauderdale, FL, USA) and a graft was inserted in each
intrastromal pocket, leaving a 2-mm clear zone between the
graft and the limbus (Fig. 1). In the mate control eye, a similar
lamellar dissection was made in the inferior temporal quadrant
without tissue insertion. No sutures were applied to any of the
grafts and all limbal wounds were closed (CU-1 10-0 nylon;
Alcon Surgical, Fort Worth, TX, USA).
Postoperative Medication
At the end of the surgery, animals received subconjunctival
injections of dexamethasone (1.2 mg in 0.3 mL), tobramycin
(10 mg in 0.25 mL), and cefazolin (55 mg in 0.25 mL). Sutures
were removed on day 7. During the postoperative period,
tobramycin 0.3% and dexamethasone 0.1% (Tobradex; Alcon
Canada, Inc.) and diclofenac 0.1% drops (Voltaren Ophthalmic;
Novartis Pharmaceuticals Corp., East Hanover, NJ, USA) were
applied three times a day for the first week and tapered over 1
month. No systemic antibiotics or steroids were given.
Prophylactic famciclovir (Famvir 125 mg/day per OS; Novartis
Pharmaceutical Corp.) was given during the entire study
period.
Standard Follow-up
Animals were examined before surgery, daily from postoperative
days 1 to 4, on days 7, 8, 10, 15, 18, 22, 25, and 30, and once a
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week for the last 3 months. Each ophthalmic examination
included slit-lamp photography (Haag-Streit, Bern, Switzerland);
intraocular pressure measurement (Perkins handheld Tonometer
Mk2; Haag-Streit, Edinburgh, UK); and central and midperipheral
corneal pachymetry (ultrasound pachymeter SP 3000; Tomey,
Nagoya, Japan). Two independent trained observers made all
corneal examinations. Eyes were checked for graft clarity, signs
of infection, inflammation, rejection, and neovascularization.
Graft transparency was quantified according to a subjective 0 to
þ4 scale30 (4þ: clear graft allowing full visualization of iris details;
3þ: slight opacity with iris/lens details easily visible; 2þ: mild
opacity, iris/lens still visible; 1þ: moderate opacity with no iris/
lens details; and 0: opaque cornea). The presence of cells and
flare in the anterior chamber was used to quantify inflammation
according to a 0 to þ4 scale.31 Corneal neovascularization was
described in terms of superficial or deep, length, number of
clock hours of limbal involvement, and flow rate (0: ghost vessel;
þ1: low flow;þ2: high flow).
Corneal Sensitivity. Corneal sensitivity was measured
using an esthesiometer (Cochet-Bonnet, 12/100 mm nylon
thread; Luneau, Chartres, France).32,33 On an awake and quiet
animal, the nylon monofilament was applied perpendicularly
to the corneal surface and shortened by 0.5-cm steps, from 6.0
cm (soft) to 0.5 cm (rigid). The longest filament length
generating a blink reflex in more than half of five applications
was recorded as the corneal sensitivity threshold. Measure-
ments were taken centrally and in the four zones of interest.
Optical Coherence Tomography (OCT). Real-time OCT
(Thorlabs, Inc., Newton, NJ, USA) was used to obtain in vivo
noncontact, two-dimensional, cross-sectional images with
resolution in the order of 4.4 lm. Corneal and graft thicknesses
and graft depth were measured using ImageJ software (http://
imagej.nih.gov/ij/; provided in the public domain by the
National Institutes of Health [NIH], Bethesda, MD, USA).34
The central, superior nasal, and inferior temporal zones of both
corneas were studied. We performed OCT on days 3, 15, 30,
44, and months 2, 3, and 4 after surgery. Six cross-sectional
images (four horizontal and two vertical) were acquired for
each zone of interest.
Specular Microscopy. Noncontact specular microscopy
(Konan Medical, Inc., Nishinomiya, Hyogo, Japan) was
performed before and 4 months after surgery to assess integrity
of the corneal endothelium. This posterior monolayer of cells
is responsible for actively dehydrating the cornea in order to
maintain its transparency.35 A minimum of 100 cells per cornea
were counted (KSS-409SP software, version 2.10, Cellchek XL;
Konan Medical, Inc.).
Postmortem Assessment
Animals were euthanized on day 114 (pentobarbital sodium 3
mL/2.5–5 kg intravenously). Grafted and control eyes were
enucleated and examined. Wide angle OCT (Visante 1000; Carl
Zeiss Meditec, Dublin, CA, USA) was performed to document
the full corneal width from limbus to limbus.
Confocal Microscopy. Confocal microscopy (Rostock
cornea module of Heidelberg Retina Tomograph II: RCM/HRT
II; Heidelberg Engineering GmbH, Heidelberg, Germany) was
performed on all eyes. Images (400 3 400 lm; 384 3 384
pixels) were obtained with a transversal optical resolution of 2
lm, an axial optical resolution of 4 lm and an acquisition time
of 0.024 seconds. Semiautomated sequences of 30 images with
incremental steps of 2 lm were obtained from epithelium to
endothelium, in the central, superior nasal, and inferior
temporal zones of all corneas.
Nerve fiber analyses were focused on the subbasal nerve
plexus (just anterior to Bowman’s layer; n ¼ 6 consecutive
images), the subepithelial nerve plexus (just posterior to
Bowman’s layer; n¼ 2 consecutive images) and the TE-stromal
grafts (n¼ 3 consecutive images for each anterior, middle, and
posterior third). Each nerve was only counted once. All
analyses were repeated at corresponding depth in the control
eye. The nerve tracing and analysis software (NeuronJ;
Biomedical Imaging Group, Lausanne, Switzerland and Rotter-
dam, The Netherlands) was used in combination with the
ImageJ software.34,36 A single observer masked for animal’s
identity, type of graft and clinical results made the analyses.
Five previously validated parameters were studied33,37–39:
1. Nerve count, representing the total number of nerves
observed within a 400 3 400 lm frame (expressed in
number/mm2);
2. Density (lm/mm2), defined as the cumulative length of
all nerves visible within a frame;
3. Length (lm), defined as the average length of nerves
within a frame;
4. Width (lm), defined as the average width of nerves
within a frame; and
5. Branching, which was described as present or absent.
Histology, Electron Microscopy, and Indirect Immu-
nofluorescence. Histology, electron microscopy, and indirect
immunofluorescence analyses were performed on the preop-
erative TE-stromas, on the grafts, as well as on the operated and
unoperated native controls. One quarter of each cornea was
fixed in 10% neutral buffered formalin and paraffin embedded
FIGURE 1. Surgical technique. Two 300-lm deep limbal incisions were made poles apart in the superior nasal (SN) and inferior temporal (IT)
quadrants and an intrastromal lamellar dissection was made. A graft was inserted in each of these stromal pockets, leaving a 2-mm clear zone
between the graft and the limbus. In the mate control eye, a similar lamellar dissection was made in the IT quadrant without tissue insertion. No
sutures were applied to any of the grafts and all limbal wounds were closed.
Living Corneal Stroma Transplanted in Feline Eye IOVS j October 2014 j Vol. 55 j No. 10 j 6910
FIGURE 2. Histology and immunofluorescent staining of the TE-stromas. (A, B) Histology cross-sections (Masson trichrome staining). (A) Tissue-
engineered stroma in culture prior to transplantation showing fibroblasts imbedded between six sheets of extracellular matrix (Masson trichrome
stains collagen in blue and cells in purple). N¼9 TE-stromas, n¼4 photographed sections per stroma. A representative photograph was chosen for
the figure. (B) Tissue-engineered stromal graft 4 months after implantation in the feline cornea. (N¼8 grafted corneasþ8 control corneas, n¼3 full
thickness corneal sections per grafted or control cornea. A representative picture was chosen for the figure. (C, D) Pretest in culture:
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for light microscopy. A second quarter was fixed in 2.5%
glutaraldehyde and prepared for transmission electron micros-
copy (TEM, Hitachi H-7500; Tokyo, Japan) as previously
described.30 We used TEM images (3100,000 and 3200,000)
to analyze distribution, diameter, and spacing of the stromal
collagen fibrils. Forty collagen adjacent fibrils were randomly
selected and measured in each sample. The ImageJ software
was used.34
One half of each cornea was frozen in optimal cutting
temperature solution (Somagen, Edmonton, AB, Canada) for
immunodetection.7 We fixed 20-lm cryosections 10 minutes at
208C using acetone (90%; EMD Serono Canada, Inc.,
Mississauga, ON, Canada) for all of the immunostainings
except for anti-HLA, which were fixed 10 minutes at room
temperature in 16% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA, USA) then permeabilized 30 minutes in
0.2% Tween-20 (Millipore Corp., Toronto, ON, Canada).
Primary antibodies consisted of a chicken antineurofilament
68 KDa (NF68; Millipore Corp.), a mouse anti-collagen I
(Calbiochem; VWR International, Mississauga, ON, Canada); a
rabbit anti-collagen IV human (Millipore Corp.); a rabbit anti-
collagen V (Cedarlane; Hornby, ON, Canada); and a mouse anti-
human HLA-ABC (Millipore Corp.). Goat anti-chicken conju-
gated with AlexaFluor 488, donkey anti-mouse conjugated with
AlexaFluor 488 or 594 and goat anti-rabbit conjugated with
AlexaFluor 594 or 488 (all from Invitrogen Life Technologies,
Burlington, ON, Canada) were used as secondary antibodies.
Cell nuclei were counterstained with Hoechst reagent 33258.
Fluorescence was observed using a confocal microscope
(LSM700, Carl Zeiss Canada, Ltd., Toronto, ON, Canada). One
transversal 0.36-lm image, taken in the middle of the TE-
stroma, was used for the observation of NF68. Images (319.49
3 319.49 lm; 2048 3 2048 pixels) were obtained with a z-stack
of 0.36 lm. Only one stack, taken in the middle of the TE-
stroma, was used for the observation of NF68.
Statistical Analysis
The mean 6 SD was used to describe continuous variables.
Statistical comparisons between groups were performed using
Student’s t-test derived from a mixed model ANOVA. An
unstructured covariance structure was used and the assump-
tion of normality of the residuals was assessed. The mixed
model was used to account for the correlation among multiple
measures of an outcome on the same subject at different time
points and/or different corneal zones.
RESULTS
In Vitro Characterization of the Engineered
Stromal tissue
Figures 2A through 2J illustrate the histological progression of
the TE-stromas from culture to the eye. Figure 2A shows the in
vitro corneal stroma with six sheets of extracellular matrix.
The mean thicknesses (6SD) of the engineered stromas in
culture was 61 6 15 lm (N ¼ 9, n ¼ 27; 38–100 lm). Before
transplantation, compatibility with axonal outgrowth was
assessed by seeding and culturing the TE-stromas with sensory
DRG. The sensory neurons seeded on top of the TE-stromas
yielded axonal outgrowth on the surface, as well as within the
deeper layers of the TE-stromas (Figs. 2C, 2D).
In Vivo Assessment
Graft Transparency. The 16 intrastromal grafts of the TE-
stroma laid at an average corneal depth of 272 6 50 lm (182–
417 lm). Once transferred to their natural environment, the
grafts rapidly cleared out. The average graft transparency score
improved rapidly to 3.3 6 0.4 on the first postoperative day
and 3.9 6 0.2 on day 37, after which all grafts remained clear,
allowing full visualization of the fine iris details with the same
precision as for native corneas (Figs. 3A, 3B). These grafts were
so clear that confirmation of their presence necessitated bright
tangential illumination, as shown in Figure 3A (second row).
Intraocular Inflammation and Pressure. There were no
signs of inflammation in any of the eyes prior to surgery. The
minimal intraocular inflammation observed in the anterior
chamber of all eyes (grafted and controls) on day 1 entirely
resolved within a few days (Figs. 3C, 3D). All corneas remained
avascular (a condition essential to preserve transparency) and
no signs of rejection, such as graft edema, stromal infiltration
or keratic precipitates, were seen at any time in any of the
grafted eyes. Beside a small and transient rise early after
surgery, intraocular pressure remained unaffected by surgery
(Fig. 3E).
Endothelial Cell Density and Graft Thickness. Endo-
thelial cell counts remained unchanged (preop grafted eyes:
2521 6 197, postop grafted eyes: 2470 6 139 cells/mm2, P¼
0.182; preop control eyes: 2490 6 181, postop control eyes:
2493 6 150, P¼0.928) and endothelial function unaffected, as
corroborated by the rapid resorption of graft edema. The
average graft thickness decreased from 44.5 6 7.8 lm on day 3
to 31.2 6 4.9 on day 114 (P  0.0001; Fig. 3F).
Corneal Sensitivity Assessed by Esthesiometry
Postoperative recovery of corneal sensitivity is illustrated in
Figure 3G. Before surgery, the average corneal sensitivity was
5.4 6 0.5 cm in the central cornea, 2.5 6 0.8 cm in the
superior nasal midperiphery and 2.7 6 0.8 cm in the inferior
temporal midperiphery, with no differences between the two
eyes (P  1.000). Surgery resulted in a significant decrease in
corneal sensitivity in all midperipheral zones where the cornea
was cut, whether a graft was inserted or not. Sensitivity
progressively returned to normal during the study period in all
the midperipheral zones (preop: 2.6 6 0.8 cm; day 3: 0.1 6
0.2 cm [P  0.0001]; day 114: 3.1 6 0.6 cm [P ¼ 0.002]).
Sensitivity in the central cornea was not affected by surgery (P
¼ 0.196). By the end of the study, all sensitivity values
converged to a mean value of 6.0 6 0.0 cm in the central
cornea and 3.1 6 0.6 cm in the midperiphery. The slight
immunofluorescent staining of a subgroup of TE-stromas seeded with DRGs. None of the TE-stromas seeded with DRGs were transplanted in vivo.
(C) En face view showing neurite outgrowth from the DRG cell bodies (NF68; green). Representative picture of four TE-stromas. (D) Cross-sectional
view showing detection of the 68-kDa neurofilament (NF68; green) across the entire tissue thickness. We visualized the TE-stroma using an antibody
directed specifically toward human type IV collagen (Coll IV, red). Cell nuclei were counterstained with Hoechst (blue). Representative picture of
three TE-stromas. (E) Immunofluorescent staining of the TE-stromal graft 4 months after transplantation (NF68; green) and type IV collagen (red).
Cell nuclei were counterstained with Hoechst (blue). (F–I) Immunofluorescent staining of the TE-stromal grafts 4 months after transplantation. (F)
Type I collagen (red). (G) Type V collagen (green). (H) Hoechst staining (blue). (I) Merge of (F–H) N¼ 8 grafted corneas. A representative region
was chosen for the figure. (J) Human–HLA-ABC staining of a human TE-stroma transplanted in the feline eye, 4 months after transplantation. The
dotted lines delineate the grafted TE-stroma. N¼ 3 grafted corneas. A representative region was chosen for the figure. Scale bars: 20 lm (A); 50 lM
(B–J).
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FIGURE 3. Clinical outcome of the TE-intrastromal grafts. (A) Representative slit-lamp photos 4 days (column 1), 1 month (column 2), and 4
months (column 3) after transplantation of a TE-stroma in the superior nasal quadrant. Regular diffuse illumination (first row) does not allow
visualization of the clear graft, which can only be seen with direct tangential illumination (second row; arrow; same graft and 310 magnification for
all six photographs). (B–G) Clinical evolution of grafted and control eyes. (B) Transparency score. (C) Anterior chamber cell score. (D) Anterior
chamber flare score. (E) Intraocular pressure. (F) Graft thickness. (G) Esthesiometry. The parameters described in this figure were measured in all
eyes at all indicated time points, with no missing data. The most representative photos are shown.
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increase above the preoperative values (P  0.0001) was
attributed to the increased level of confidence of the animals.
Histology
Histopathology 4 months after transplantation showed smooth
integration of the grafts, without surrounding scar tissue,
inflammatory cellular infiltration, or vascular invasion (Fig. 2B).
The multilayered epithelium and the endothelial monolayer
appeared undisturbed. The stromal grafts were homogeneous,
with a more compact lamellar arrangement than that seen in
culture. Fibroblasts were more numerous in the grafts than in
the host stroma.
Nerves, Cells, and Collagen Content Assessed by
Immunofluorescence
The presence of multiple nerve filaments within these grafts 4
months after transplantation confirmed active reinnervation by
the host (Fig. 2E). These new nerves tended to grow between
and parallel to the stromal lamellae of the graft. Immunostain-
ing of the xenogeneic grafts using an anti-human HLA antibody
allowed to confirm that the transplanted human cells were still
present in the TE-stroma 4 months after transplantation (Fig.
2J). A specific anti-human collagen IV antibody also revealed
that human collagen was also present 4 months after
transplantation (Fig. 2E). The expression of collagen types I
and V in the TE-stroma was stronger in culture than after
transplantation. By the end of the study, the expression of
collagen I in the native and TE-stromas was similar, while that
of collagen V was similar (Figs. 2F–I) or stronger in the grafts
than in the native stroma.
Corneal Innervation Assessed by Confocal
Microscopy
Confocal microscopy confirmed that all corneal layers were
innervated after 4 months (Figs. 4A–I). The new nerves within
the grafts were different from the mature nerves of the
unoperated control corneas (Figs. 4J–M). They showed higher
nerve counts (33 6 14 /mm2 vs. 14 6 15 /mm2; P < 0.001)
and greater nerve densities (3708 6 1237 lm/mm2 vs. 2024 6
1374 lm/mm2; P ¼ 0.002), and they tended to be shorter (20
6 7 lm vs. 33 6 20 lm, P¼ 0.064) than the mature nerves of
the unoperated controls at corresponding stromal depth.
Although not statistically significant, they also appeared to be
wider (4 6 2 lm vs. 3 6 1 lm, P ¼ 0.143) and only rarely
showed branching (6% vs. 29%, P ¼ 0.106).
The new nerves within the grafts were identical (nerve
counts, density, length, width, and branching) to the new
nerves found in the recipient’s stroma at the level of the
incisions without a graft (P > 0.05). At the level of the subbasal
and subepithelial plexus, no substantial differences were noted
beside an increase in nerve density in the operated zones
compared with the unoperated zones, both at the subbasal (P
¼ 0.022) and subepithelial (P ¼ 0.016) levels.
Transmission Electron Microscopy
Corneal Stromal Fibroblasts. Before transplantation,
abundant fibroblasts were present throughout the TE-stromas
(Figs. 5A, 5B). Signs of activation included an increased density
in rough endoplasmic reticulum (RER) and Golgi apparatus,
numerous mitochondria, chromatin margination, and promi-
nent nucleoli (Figs. 5C, 5D).
Four months after transplantation (Figs. 5E–H), fibroblast
density in the TE-stromal grafts was still greater than in the
recipient’s stroma. The fibroblasts were much thinner and
more elongated than in culture, their morphology being closer
to that of the recipient keratocytes, which are shown in Figures
5I through 5L. While most of the features of activated
fibroblasts were absent, these cells had not yet returned to a
resting state.
Extracellular Matrix and Collagen Fibrils. The TE-
stroma in culture showed layers of wavy collagen fibrils
surrounded by abundant extracellular matrix (Figs. 5A–C, 5M).
Four months after transplantation, the TE-stromal grafts
showed a more compact and regular architecture (Figs. 5E–
H, 5N), although still not as regular as that of the native stroma
(Figs. 5I–L, 5O, 5P). Regularity of collagen fibrils was greater in
the anterior part of the grafts compared with the posterior part
of the grafts.
The mean space between collagen fibrils in the TE-stromal
grafts decreased after transplantation, getting closer to that
measured in nonoperated controls (P < 0.0001). Interfibrillar
spacing was also larger in the host stroma surrounding the
grafts (i.e., exposed to surgical manipulations) than in
nonoperated controls (P < 0.0001). Mean interfibrillar
distances are reported in the Table and typical examples are
illustrated in Figures 5M through 5P.
The mean collagen fibril diameter in the TE-stromal grafts
increased slightly after transplantation (P < 0.0001) and
remained larger than that of the nonoperated controls (P <
0.001). The collagen fibrils surrounding the graft were also
thicker than in the nonoperated controls (P < 0.0001; Figs. 5O,
5P; Table).
Stromal Grafts Engineered From Keratocytes of
Feline Versus Human Origin. No differences were found
between the TE-grafts of feline versus human origin (transpar-
ency scores, graft thickness, corneal innervation assessed by
confocal microscopy, and collagen fibrils diameter and spacing
as assessed by TEM; P > 0.05).
DISCUSSION
We present herein the first in vivo results on the transplanta-
tion of a corneal stroma entirely engineered in vitro from
corneal stromal cells, without the addition of exogenous
material or scaffold. The TE-corneal stromas in culture showed
the lamellar structure characteristic of the native corneal
stroma and were biocompatible to neurite outgrowth. Four
months after transplantation in a feline animal model, the TE-
stromal grafts were clinically functional and well tolerated by
the eye. They were transparent, with no adverse effect noted
on the normal organization and function of the recipient’s
epithelial, stromal, and endothelial corneal layers, and no
inflammatory reaction. There were no signs of immune
rejection. Corneal sensitivity returned to preoperative level
and reinnervation of the grafts was confirmed by confocal
microscopy and immunofluorescence.
Development of the Corneal Stroma
In several aspects, this corneal stroma, tissue-engineered using
the self-assembly approach and transplanted in the living eye,
followed a structural development similar to that occurring in
the embryonic eye.40 Proliferation of the stromal cells was
followed by the deposition of layers of extracellular matrix,
with loosely parallel collagen fibrils. Transplantation resulted in
significant thinning and compaction of the TE-stroma, with a
concomitant increase in tissue transparency. Fibroblasts’
morphology evolved from a rounded to a flat shape more
typical of mature keratocytes. The collagen fibrils became
more parallel and tightly packed, resulting in an ultrastructure
increasingly homogenous and similar to that of the mature
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FIGURE 4. Corneal reinnervation 4 months after surgery. (A–I) Representative confocal images illustrating the corneal nerves within the subbasal
plexus (A–C), the subepithelial plexus (D–F) and the stroma (G–I), at the level of the TE-stromal graft (A, D, G), the inferior temporal quadrant of
the control eye where only a surgical incision was made (B, E, H), and the superior nasal quadrant of the control eye with no incision (C, F, I). (J–M)
Quantification of reinnervation, based on nerve count (J), nerve density (K), nerve length (L) and nerve width (M) at the level of the TE-stromal
graft, the superior nasal quadrant of control eye with no incision and the inferior temporal quadrant of control eye with incision. The parameters
described in this figure were measured in all eyes at all indicated levels, with no missing data. Each nerve was only counted once. The most
representative photos are shown. Scale bar: 50 lm (same for all photographs).
Living Corneal Stroma Transplanted in Feline Eye IOVS j October 2014 j Vol. 55 j No. 10 j 6915
native stroma. A greater regularity was observed in the anterior
part of the grafts. The TE-stroma expressed collagen types I and
V, two types of fibrillar collagen normally expressed in the
native cornea. The fact that the extracellular matrix secreted
and assembled by the corneal fibroblasts generated a stroma
that did not clinically resemble scar tissue and the absence of
inflammatory reaction might in part distinguish this self-
engineering process from standard wound healing.
Corneal Transparency
Transparency of a bioengineered stroma, a sine qua non
condition to light transmission and vision, and maintenance of
this transparency once implanted in the living eye, is
challenging. Current understanding of corneal transparency
favors the role of fibril spacing, which needs to be much
smaller than the light wavelength and such that fluctuations in
refractive index are smaller than half the light wavelength.41
FIGURE 5. Transmission electron microscopy of the TE-stroma before and 4 months after surgery. (A–D) Tissue-engineered stroma in culture prior
to transplantation. Thick layers of wavy stromal lamellae and numerous fibroblasts (A), most of them activated and in close proximity to each other
(B, C). The prominent RER, numerous mitochondria, and vacuoles sign the high level of activity of these cells (D). (E–H) Tissue-engineered stromal
graft 4 months after transplantation. The TE-stroma shows a more compact architecture than it did in culture. Fibroblast density is still superior to
that of the recipient’s native stroma (E). Fibroblasts are thinner and more elongated than they were in culture (G–H), showing less prominent RER,
Golgi, mitochondria, and chromatin margination, but these cells were still not resting. (I–L) Recipient’s native stroma in the contralateral eye (I, J)
and close to the graft (K, L). The fibroblasts close to the surgical areas (K, L) are larger and more active than those in the unoperated control areas.
(M–P) Transversal view of the collagen fibrils in the TE-stroma before transplantation (M), in the TE-stromal graft 4 months after transplantation (N),
in the recipient’s native stroma close to the graft (O), and in the recipient’s native stroma of the control eye (P). n¼ 9 TE-stromas in culture and 16
ex vivo corneas. Representative photos are shown. Scale bars: 10 lm (A, E, I); 2 lm (B, C); 500 nm (D, F–H, J–P).
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Light scattering in the cornea increases and transparency
decreases when changes in the index of refraction occur
locally in a zone of comparable size or larger than the
wavelength, such as when the spatial arrangement of the
fibrils is modified or when the fibril diameter or density
increases.42 Taking advantage of the natural properties of the
extracellular matrix deposited by the stromal cells and the
spontaneous orientation of these fibrils43,44 allows the
engineering of a transparent stroma. While encouraging
progress has been made in the past decade for the production
of stromal substitutes, transparency still needs to be improved
in anticipation of human use.15,45–49 The delay in corneal
transparency rehabilitation also has to be considered. In this
study, we have gone a step further with a TE-stromal graft,
allowing early and stable visualization of fine iris details during
the 4-month observation period, a sign that confirms its
transparency. The discrete haze only perceptible with tangen-
tial illumination allows us to believe that the TE-lamellar
transplants proposed herein are very close to an optimal
functional solution. Long-term studies will say if this mild
residual haze resorbs with time.
Stromal Fibrillar Spacing and Diameter
The main function of native keratocytes in vivo is to maintain
stromal composition by synthesizing new collagen and
proteoglycans, and secreting collagenases and other enzymes
to degrade old matrix.50 Proteoglycans are known to play a
major role in regulating collagen fibrils size, diameter, and
spatial distribution, and they are involved in the control of the
swelling properties of the matrix.51,52 A variety of factors have
also been shown to influence fibrillogenesis. Among them,
interaction between type V and type I collagen would be at
least partially responsible for modulating collagen fibril
diameter in the corneal stroma.53–55 The composition of the
self-assembled extracellular matrix has been reported else-
where.56
In this study, the collagen fibril diameter and spacing within
our TE-stromas compared favorably with literature reports
(Table). In culture, the interfibrillar spacing was closer to
native stroma than what has been reported by others using
different techniques57,58 and 4 months after transplantation, it
was even closer to that reported for the native human
stroma.59 The mean collagen fibril diameter of our TE-stromas
in culture was similar to that produced by the other
groups,57,58,60–63 stromal collagen fibrils produced in vitro
being larger than native stromal fibrils.59,64–66 Four months
after transplantation, fibrils were still somewhat larger than
usually found in the native stroma.
Reinnervation
The ability of a TE-stroma to allow reinnervation is of primary
importance. Corneal nerves contribute to the maintenance of a
healthy ocular surface, exert a trophic influence on the corneal
epithelium, and promote wound healing after eye injury.67 A
dysfunctional corneal innervation induces a degenerative
neurotrophic keratitis,68 resulting in chronic epithelial defects
and increased risk for infection, stromal ulceration, stromal melt,
and perforation. The feline model used herein was interesting
because of the known similarities in innervation and sensitivity
recovery between the cat and primate corneas.32,69
In this study, all stromal grafts were innervated 4 months
after transplantation. As all TE-stromal grafts were devoid of
any type of DRG or neural component at the time of
transplantation, all neurons seen in the grafts in the living
eye originated from the recipient. This provides additional
evidence of their biointegration. The reinnervation patterns of
the native and tissue-engineered stromal layers were similar,
the new nerves being more numerous, shorter, thicker, and
showing less branching than the mature nerves of the
unoperated corneas.
The pattern70,71 and timing of reinnervation of the TE-
stromal grafts were similar to those reported for native corneal
grafts in human subjects. Reinnervation of native grafts is
known to start 2 to 6 months after transplantation38,71,72 and
continue to progress for several decades after transplanta-
tion.73 Sensitivity recovery was also similar to that reported
after corneal surgery.71,74
Immunological Tolerance
None of our grafts showed any signs of immune reaction
despite the fact that:
1. Half of these TE-stromas were produced using xenoge-
neic human cells;
2. These grafts were inserted in the corneal periphery, very
close to the limbal vasculature; and
3. Animals received only a very short course of low dose
topical steroids (much less than the 1 year and more
regimen routinely administered to human subjects after
corneal transplantation).75
The eye benefits from immune privilege76–79 and corneal
transplants are the least-rejected among all organ transplants.80
Furthermore, corneal rejection is typically directed against the
corneal endothelium,80 while stromal rejection appears to be
particularly rare.81 However, if the cellular content becomes a
concern,82 the TE-stromal grafts could be decellularized prior
TABLE. Collagen Fibril Diameter and Spacing
Spacing Between Fibrils, nm Fibril Diameter, nm
Present study
TE-stroma in culture (N ¼ 9 TE-stromas; n ¼ 40 fibrils)* 32.0 6 9.1 35.5 6 6.0
TE-stroma at 4 months (N ¼ 8 grafts; n ¼ 40 fibrils) 25.0 6 5.8† 39.5 6 4.3†
Native tissue adjacent to graft (N ¼ 8; n ¼ 40) 22.2 6 4.2‡ 36.3 6 3.5‡
Normal native control (N ¼ 8; n ¼ 40) 19.9 6 3.9§ 34.0 6 3.2§
Literature
In culture 56.1–60.957,58 30–48.657,58,60–63
Native stroma 19.6–20.959 22.7–34.059,64–66
* N indicates the number of tested tissues (TE-stromas, grafts, or controls) and n indicates the number of fibrils measured in each tissue.
Statistically significant differences.
† Between values in culture versus 4 months after transplantation (P <0.0001).
‡ Between native tissue adjacent versus normal native control (P < 0.0001).
§ Between the TE-stroma at 4 months versus normal native control (spacing: P < 0.0001; diameter: P < 0.001).
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to transplantation (for instance by three freeze–thaw cycles).83
Another alternative would be to engineer stromal grafts from
autologous cells, which would definitely eliminate the risk of
immune rejection.
Translational Potential, Limitations, and Further
Work
We have demonstrated the biocompatibility and functionality
of lamellar TE-stromal grafts 4 months after intrastromal
transplantation in the living feline eye. Quantitative character-
ization of the optical and mechanical properties of these grafts
and implanted corneas will be needed next. Optical assess-
ment could involve spectral transmittance,84 absorbance, and
scattering measures, while biomechanical assessment should
include tensile strength measurements.44 Performance of these
TE-stromal grafts will then be tested for the rehabilitation of
diseased corneas. Lamellar replacement of scarred corneal
layers or the filling of a pathological corneal thinning are two
examples of potential clinical applications. Intracorneal filling
using a biocompatible, transparent, and malleable TE-stroma is
presently not a therapeutic modality clinically available. This
concept could be the basis for multiple types of applications in
corneal interventional surgery, including compensation for a
wide range of pathological corneal thinning, such as those
encountered in Terrien marginal degeneration or after infec-
tious keratitis or trauma. Intrastromal filling in these cases may
allow to avoid more invasive and higher risk interventions,
such as a patch graft or a full thickness corneal transplantation.
Only minimal re-expansion of the stromal volume may
sometimes be necessary to rehabilitate these eyes. These TE-
stromas were not designed for full thickness stromal replace-
ment and their implantation necessitates residual stromal
support. Although these multilayered TE-stromas could hold
a suture, no sutures need to be applied to the grafts with the
intrastromal lamellar transplantation technique, thus eliminat-
ing related tissue compression, scarring, and astigmatism.
Furthermore, the multilayer concept described herein may
allow the thickness of the graft to adapt to individual clinical
needs. There are no specific technical barriers for the transfer
of these concepts to the clinic. The self-assembly approach
described herein for the engineering of stromal substitutes is
currently successfully used to generate other tissues (skin) for
human subjects and the surgical insertion of an intrastromal
graft constitutes no challenge for the corneal surgeon. Other
applications of TE-stromas (that would require additional
investigation) may also include their use as carrier for the in
vivo transplantation of a tissue-engineered corneal endotheli-
um.6–8,30
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Élodie Samson for statistical analyses.
Supported by the Académie Nationale de Médecine, Paris, France;
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